Lexaria Bioscience Corp. (LEXX) News
Follow Lexaria Bioscience Corp. (LEXX) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 11 public stories across 9 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
M
Lexaria Bioscience raises $7.9M and extends cash runway to 2027
Lexaria Bioscience says it secured $7.9M via an Australian tax refund and institutional financing priced at $12.92/share, extending cash runway through 2027 with no plans for additional 2026 financings.
EQUITY | Sep 17, 2026, 01:11 PM UTC
M
Lexaria closes warrant exercise for about $5.9 million in gross proceeds
Lexaria Bioscience Corp. closed its previously announced exercise of outstanding warrants, raising approximately $5.9 million in gross proceeds. The company says the warrants covered an aggregate of 453…
EQUITY | Sep 09, 2026, 08:16 PM UTC
L
Lexaria Bioscience raises about $5.9 million via warrant exercise
Lexaria Bioscience secured about $5.9 million gross proceeds after holders exercised 453,969 existing warrants at $12.92 per share under inducement offer letters. The company will issue new unregistered Series A and Seri
EQUITY | Sep 09, 2026, 02:14 PM UTC
L
Lexaria enters definitive agreements for immediate warrant exercises
Lexaria Bioscience said it entered definitive agreements for the immediate exercise of certain outstanding warrants, targeting approximately $5.9 million in gross proceeds.
EQUITY | Sep 08, 2026, 12:00 PM UTC
L
Lexaria to present at H.C. Wainwright 28th Global Investment Conference
Lexaria Bioscience Corp. (NASDAQ:LEXX) said it will participate in the H.C. Wainwright 28th Annual Global Investment Conference.
EQUITY | Sep 04, 2026, 01:20 PM UTC
L
Lexaria Bioscience gets AUD 3.67 million R&D tax credit
Lexaria Bioscience received an AUD 3,666,611.98 Australian R&D tax credit, or USD 2.6 million, tied to its GLP-1 clinical study.
REGULATION | Sep 01, 2026, 01:24 PM UTC
L
Lexaria receives USD million Australian tax rebate cash payment
Lexaria Bioscience Corp. says it has received a cash tax rebate payment related to its 2025 Australian human study results.
EQUITY | Sep 01, 2026, 01:15 PM UTC
M
US Stocks Announce Reverse Splits
Multiple US stocks undergo reverse splits
EQUITY | Aug 03, 2026, 09:05 AM UTC
L
US Stocks Undergo Reverse Splits
Multiple US stocks undergo reverse splits
EQUITY | Aug 02, 2026, 12:49 PM UTC
M
LEXX: Begins Dosing
Lexaria's human study GLP-1-H26-7 has begun dosing on schedule
EQUITY | Jun 25, 2026, 01:10 PM UTC
L
LEXX: Animal Study Begins
Lexaria's animal study GLP-1-A26-1 has begun dosing on schedule
EQUITY | Jun 23, 2026, 01:26 PM UTC